Clinical Trials Logo

Nervous System Malformations clinical trials

View clinical trials related to Nervous System Malformations.

Filter by:

NCT ID: NCT06019182 Recruiting - Obesity Clinical Trials

MEHMO Natural History and Biomarkers

Start date: June 26, 2024
Phase:
Study type: Observational

This observational natural history study will follow individuals with MEHMO (Mental disability, Epileptic seizure, Hypopituitarism/Hypogenitalism, Microcephaly, Obesity) syndrome or an eIF2-pathway related disorder, who have symptoms such as intellectual delay, seizures, abnormal hormone and blood sugar levels, and decreased motor skills. No current treatment for these conditions is available. A major impediment to the testing of potential therapeutic interventions is the lack of well-defined outcome measures. This protocol seeks to identify biochemical and clinical markers to monitor disease progression, and better understand the natural history of these conditions. Any person diagnosed with MEHMO syndrome or related conditions, who can travel to the NIH Clinical Center can participate in this study. The study involves: - General health assessment and evaluation - Imaging studies - Laboratory tests - Collection of blood, urine, spinal fluid, skin biopsy.

NCT ID: NCT05971329 Not yet recruiting - Disc Degeneration Clinical Trials

Pilot Study of ZetaFuseā„¢ Bone Graft for the Treatment of Cervical Degenerative Disc Disease

Start date: September 2024
Phase: Early Phase 1
Study type: Interventional

The goal of this pilot clinical trial is to test the safety and preliminary performance of the ZetaFuse Bone Graft in patient requiring fusion of the C3-C7 vertebral bones due to pain or loss of neurological function. Participants will be treated with ZetaFuse during surgical intervention to reduce pain and the loss of neurological function.

NCT ID: NCT05778279 Recruiting - Clinical trials for Central Nervous System Diseases

Role of New High Resolution Ultrasonographic Modalities for Diagnosis of Fetal Nervous System Anomalies

Start date: September 30, 2024
Phase:
Study type: Observational

The fetal CNS screening examination during the mid-trimester scan in low-risk pregnancies should include evaluation of the fetal head and spine, using transabdominal sonography. Evaluation of two axial planes allows visualization of the relevant cerebral structures to assess the anatomic integrity of the fetal brain.These planes are commonly referred to as the transventricular and transcerebellar planes. A third plane, the so-called transthalamic plane, is frequently added, mostly for the purpose of biometry. Structures that should be noted in the routine examination include the lateral ventricles, the cerebellum, the cisterna magna, and the cavum septi pellucidi (CSP). Head shape and brain texture should also be noted on these views.

NCT ID: NCT05771922 Recruiting - Clinical trials for Ultrasound Therapy; Complications Anomaly Central Nervous System Diseases

Implication of New High Resolution Ultrasonographic Modalities for Diagnosis of Fetal Nervous System Anomalies

Start date: November 30, 2024
Phase:
Study type: Observational

The fetal CNS screening examination during the mid-trimester scan in low-risk pregnancies should include evaluation of the fetal head and spine, using transabdominal sonography. Evaluation of two axial planes allows visualization of the relevant cerebral structures to assess the anatomic integrity of the fetal brain.These planes are commonly referred to as the transventricular and transcerebellar planes. A third plane, the so-called transthalamic plane, is frequently added, mostly for the purpose of biometry. Structures that should be noted in the routine examination include the lateral ventricles, the cerebellum, the cisterna magna, and the cavum septi pellucidi (CSP). Head shape and brain texture should also be noted on these views.

NCT ID: NCT05613868 Recruiting - Clinical trials for Aicardi-Goutières Syndrome (AGS)

TPN-101 in Aicardi-Goutières Syndrome (AGS)

Start date: March 15, 2023
Phase: Phase 2
Study type: Interventional

A phase 2a multi-center, open-label single dose level study of TPN-101 in Patients with Aicardi-Goutières Syndrome (AGS)

NCT ID: NCT04731103 Completed - Clinical trials for Aicardi-Goutières Syndrome

Inhibition of Reverse Transcription in Aicardi-Goutières Syndrome

AGS-RTI
Start date: August 24, 2022
Phase: Phase 2
Study type: Interventional

Aicardi-Goutières syndrome (AGS) is a disease of children, particularly affecting the brain and the skin. There is a close link between AGS and increased amounts of a chemical called interferon. Normally humans only produce interferon when they are infected with a virus. In AGS, there is no viral infection. Instead, the cells in the cells of affected patients are confused into thinking that their own genetic material is coming from a virus. As a result they produce interferon all the time, which acts as a poison that damages the cells. The Investigators wish to treat AGS patients with drugs called reverse transcriptase inhibitors (RTIs), used to fight the HIV-1 virus that causes AIDS. The investigators will monitor the effect of treatment on interferon levels, and look at other markers which might give us clues to how the drugs are working. The trial is funded by the Medical Research Council, and involves experts based in Edinburgh, Birmingham, Manchester and Great Ormond Street Hospital.

NCT ID: NCT04643548 Recruiting - Delirium Clinical Trials

WHO Covid 19 - Neurological Abnormalities in SARS-CoV-2 ICU Patients

NeuroCovid
Start date: October 13, 2020
Phase:
Study type: Observational

The SARS-CoV-2 epidemic is leading to a large number of patients in intensive care units due to severe hypoxemic pneumonia. After an acute phase that may require controlled mechanical ventilation and deep sedation, removal of sedation often reveals a pathological awakening in the vast majority of patients. This encephalopathy state remains, to date and to our knowledge, unexplained. Clinical features do not appear to fully correlate with regular delirium. This encephalopathy might be explained by deep and prolonged hypoxemia, a wide use of sedation drugs, systemic inflammation or the hostile ICU environment.

NCT ID: NCT04170985 Completed - Neurologic Disorder Clinical Trials

NeuroSeq: A Prospective Trial to Evaluate the Diagnostic Yield of Whole Genome Sequencing (WGS) in Adult Neurology

NeuroSEQ
Start date: November 18, 2019
Phase:
Study type: Observational

Prospective, multi-site, single-arm study to evaluate the diagnostic yield of cWGS in adults with neurological disorders. A single cohort naive of genetic testing will receive standard of care testing for 180 days followed by cWGS. The cohort will be followed for a total of 365 days following enrollment.

NCT ID: NCT03921554 Completed - Clinical trials for Aicardi Goutieres Syndrome

JAK Inhibitor Treatment in AGS

Start date: June 3, 2019
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to assess safety as well as efficacy of baricitinib, a Janus Kinase (JAK) inhibitor, in patients with Aicardi Goutières Syndrome (AGS), a multisystem heritable disorder of the innate immunity resulting in excessive interferon production

NCT ID: NCT03482141 Completed - Skeletal Anomalies Clinical Trials

Clinical Utility of Prenatal Whole Exome Sequencing

PWES
Start date: August 1, 2017
Phase: N/A
Study type: Interventional

The investigator aims to examine the clinical utility of WES, including assessment of a variety of health-related and reproductive outcomes in undiagnosed prenatal cases.